Keytruda

NHS England sees off AbbVie's Hep C legal challenge

CAR-T therapy (Gilead/Kite’s Yescarta and Novartis’ Kymriah) and a deal to make the MSD’s groundbreaking Keytruda available for routine use for lung cancer patients on the NHS.

The UK’s new five-year pricing agreement

of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year.

EU approval for Opdivo combo in renal cell cancer

However, the company has its IO rivals hot on its heels, with MSD’s Keytruda and Merck and Pfizer’s Bavencio both in late stage studies in combination with Pfizer’s ... This is necessary as it now looks impossible for Opdivo to catch its big rival

Chinese biotechs aim PD-L1 antibody at hepatitis B

Front-runners in the immuno-oncology category such as Bristol-Myers Squibb (BMS) with Opdivo (nivolumab) and Merck &Co/MSD with Keytruda (pembrolizumab) have not started trialling their blockbuster drugs in

BMS and Celgene deal sparks debate on pharma profit motive, more M&A

Meanwhile Merck &Co has had enormous success with its immuno-oncology market leader Keytruda, but the rest of its portfolio is looking distinctly threadbare by comparison, with some investors eager for

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]